Bioconversion of vitamin D3 to bioactive calcifediol and calcitriol as high-value compounds.

Biological catalysis is an important approach for the production of high-value-added compounds, especially for products with complex structures. Limited by the complex steps of chemical synthesis and low yields, the bioconversion of vitamin D3 (VD3) to calcifediol and calcitriol, which are natural steroid products with high added value and significantly higher biological activity compared to VD3, is probably the most promising strategy for calcifediol and calcitriol production, and can be used as an alternative method for chemical synthesis. The conversion efficiency of VD3 to calcifediol and calcitriol has continued to rise in the past few decades with the help of several different VD3 hydroxylases, mostly cytochrome P450s (CYPs), and newly isolated strains. The production of calcifediol and calcitriol can be systematically increased in different ways. Specific CYPs and steroid C25 dehydrogenase (S25DH), as VD3 hydroxylases, are capable of converting VD3 to calcifediol and calcitriol. Some isolated actinomycetes have also been exploited for fermentative production of calcifediol and calcitriol, although the VD3 hydroxylases of these strains have not been elucidated. With the rapid development of synthetic biology and enzyme engineering, quite a lot of advances in bioproduction of calcifediol and calcitriol has been achieved in recent years. Therefore, here we review the successful strategies of promoting VD3 hydroxylation and provide some perspective on how to further improve the bioconversion of VD3 to calcifediol and calcitriol.

Background

Vitamin D3 (VD3) is an essential steroid hormone in the human body and a fat-soluble prohormone. In addition to being obtained from food, VD3 can be synthesized in the human body by ultraviolet irradiation using 7-dehydrocholesterol as a precursor. VD3 has an important role in regulating calcium and phosphorus metabolism and controlling the growth and development of bone cells [1]. However, the biological activity of VD3 is relatively low compared with that of its active forms. In the human body, two-step hydroxylation under the catalysis of cytochrome P450s (CYPs) is required for its full biological activity. VD3 is first converted to 25(OH)VD3 (calcifediol) in the liver, mainly but not exclusively by CYP2R1, and then further converted to 1α,25(OH)2VD3 (calcitriol) by CYP27B1 in the kidney to gain its full activity [2]. VD3 helps treat osteoporosis, chronic renal dysfunction and other diseases [3, 4]. Supplementation with the hydroxylation products of VD3 instead of VD3 itself eliminates the need for the hydroxylation process in the human body, making it important for patients with abnormalities in vitamin D metabolism. It has been reported that supplementation with calcitriol is helpful for the treatment of liver [5] and kidney disorders [6], and calcifediol is used for the treatment of calcium disorders, such as rickets [7]. In addition, calcifediol or calcitriol supplementation is able to prevent cartilage diseases, improve egg production and egg quality of laying hen, and enhance reproductive performance of breeding swine in the livestock and poultry production [8-10].

At present, calcifediol and calcitriol are mainly produced by chemical synthesis, which requires complex protection and deprotection steps for the regioselective introduction of hydroxyl groups, especially for hydroxylation on C-1, limiting the industrial production [11, 12]. For example, starting with hydrindenylpropanol, Lythgoe et al. [13] synthesized des-AB-cholestane-8β,25-diol, which could be further used as a substrate for the synthesis of calcifediol. The synthesis process of des-AB-cholestane-8β,25-diol requires multiple steps and further conversion to calcifediol. Calcitriol can be obtained by condensation of 1α-hydroxylated phosphine oxide with 25-hydroxy ketone [14]. However, the substrates also require multiple steps for synthesis. Thus, compared with chemical synthesis, the bioconversion of VD3 is a successive process that comprises two (25- and 1α) or one (only 25-) hydroxylation steps. In addition, the yield of chemical synthesis of calcifediol is low (the classical approach by photochemical ring opening of steroidal Δ5,7-dienes yields less than 1%) [15]. Therefore, increasing attention is being paid to the bioconversion of VD3 to calcifediol and calcitriol. Though hydroxylated sterols could be synthesized by transgenic Arabidopsis plants with non-heme monooxygenase [16], VD3 has not yet been reported as a substrate. Microorganisms have been a powerful tool for VD3 hydroxylation research, and in some work, the VD3 conversion rate was remarkable. Therefore, a bioconversion process with VD3 as the substrate and microorganisms as the chassis cells is promising for its simplicity and low pollution.

In the past few decades, a large number of strains expressing VD3 hydroxylases have been developed for VD3 bioconversion. A common strategy is to screen organisms with VD3 hydroxylation capabilities and then examine their calcifediol and calcitriol production abilities by fermentation. Furthermore, the characterization of VD3 hydroxylases from different sources and their heterologous expression in different host cells are also topics of particular interest in this field. These VD3 hydroxylases mainly refer to cytochrome P450s. In addition, steroid C25 dehydrogenase (S25DH) was also reported to have the ability to hydroxylate VD3 at the C-25 position. However, S25DH is sensitive to oxygen, causing a high cost for calcifediol production [17]. CYPs are the primary enzymes currently used for bioconversion of VD3 to its active forms. A variety of CYPs from mammals and bacteria (mainly from actinomycetes) that are capable of converting VD3 to calcifediol and calcitriol have been identified, and highly active mutants have been constructed. Enhanced calcifediol and calcitriol production could further benefit from the rapid development of creating new enzymes and new biochemical reactions via computational redesign of enzymes.

In general, enzymes and whole cells are two categories of biocatalysts commonly used for bioconversion [18, 19]. Here, we review advances in the characterization and engineering of VD3 hydroxylase that plays a key role in VD3 bioconversion, and progress in whole-cell bioconversion, which can use inexpensive and abundant raw materials and avoiding the addition of expensive cofactors.

VD3 hydroxylases and their protein engineering

For the synthesis of complex compounds, including calcifediol and calcitriol, enzymatic conversion has high regio- and stereoselectivity when compared with chemical synthesis. VD3 hydroxylases, most of which are CYPs, play a central role in the bioconversion of VD3 into calcifediol and calcitriol. Cytochrome P450s (CYPs) are a class of heme-containing enzymes with similar structures. CYPs catalyze a variety of reactions, mostly monooxygenation reactions, and have a wide range of substrate specificities [20]. The main CYPs related to VD3 hydroxylation are shown in Table 1 and Fig. 1.

Table 1

CYPs from different organisms and their substrate specificities

CYPs	Species	Substrates	Products	References
Mammalian CYPs
CYP27A1	Homo sapiens Rattus norvegicus (rat)	VD3 Calcifediol	Calcifediol Calcitriol	[24]
CYP27B1	Mus musculus (mouse)	VD3, Calcifediol	Calcifediol 1α(OH)VD3 Calcitriol	[23]
CYP2D25	Susscrofa domestica (pig)	VD3 Calcifediol	Calcifediol Calcitriol	[35]
CYP2J2	Homo sapiens	VD3	Calcifediol	[36]
CYP2J3	Rattus norvegicus	VD3	Calcifediol	[27]
CYP2C11	Rattus norvegicus	VD3	Calcifediol	[37]
CYP2R1	Homo sapiens	VD3	Calcifediol	[28]
Bacterial CYPs
CYP105A1	Streptomyces griseolus	VD3 Calcifediol	Calcifediol Calcitriol	[41]
CYP105A2	Pseudonocardia autotrophica	VD3	Calcifediol	[40]
CYP107CB2	Bacillus lehensis	VD3 Calcifediol	Calcifediol Calcitriol	[42]
CYP107BR1	Pseudonocardia autotrophica	VD3 Calcifediol	Calcifediol Calcitriol	[48]

Fig. 1

VD3 bioconversion process. VD3 is sequentially converted to calcifediol and calcitriol by CYPs. Some uncommon CYPs can also catalyze the conversion of VD3 to calcitrol with 1α(OH)VD3 as the intermediate. Many CYPs, such as CYP27B1, can catalyze hydroxylation at two sites, as they have relatively wide substrate specificity and regioselectivity

Mammalian and bacterial CYPs have been widely utilized for the bioproduction of calcifediol and calcitriol, the active forms of VD3. Mammalian CYPs have attracted great attention as they are associated with VD3 metabolism related diseases. Bacterial CYPs are also of great importance because of their enormous functional diversity. A unique property of bacterial CYPs is that carbon monoxide (CO), SKF-525-A and metyrapone inhibit the hydroxylase activities of bacterial CYPs. Therefore, reduced CO difference spectroscopy can be used to identify bacterial CYPs that function as VD3 hydroxylases [21, 22]. To simplify the purification of CYPs, especially mammalian CYPs, the heterologous expression of CYPs in model organisms can increase protein yield and reduce the cost [23]. Escherichia coli and yeast are ideal host cells for heterologous expression of CYPs, as they grow quickly and genetic tools for their modifications have been well developed. Given that the hydroxylation reaction of CYPs requires redox proteins to deliver electrons, it is of great importance to improve VD3 conversion rates using appropriate redox partners and coenzyme regeneration systems. Because of the existence of abundant redox proteins, actinomycetes are also becoming popular for heterologous expression of VD3 hydroxylases. With an increased understanding of the relationship between the protein structures of CYPs and their hydroxylation abilities, protein engineering has been widely applied to the evolution of CYPs in the laboratory, which aims to improve the activity of CYPs for enhanced VD3 bioconversion.

CYPs from mammals

Mammalian VD3 hydroxylases such as CYP27A1, CYP27B1, CYP2D25, CYP2J3 and CYP2R1 have been found to be able to catalyze C-25 or C-1α hydroxylation [24-28]. The CYP27A1 was the first mammalian CYP to be thoroughly studied. Saccharomyces cerevisiae expressing a modified rat CYP27A1 localized in microsomes could convert 1α(OH)VD3 to calcitriol when adrenodoxin (ADX) and NADPH-adrenodoxin reductase (ADR) were coexpresseded [24]. The ADRs from yeast and rats were unable to transfer electrons for rat CYP27A1. However, the purified bovine ADR and ADX facilitated the reaction. Therefore, the mitochondria-targeting signals of bovine ADR and ADX were removed to construct an electron transfer chain between the cytoplasm and the modified CYP27A1 that was incorporated into microsomes. The modified rat CYP27A1 could convert 1α(OH)VD3 to calcitriol with the help of the newly constructed electron transfer chain. In one study, human CYP27A1, which also belongs to the CYP27 family was expressed in E. coli to examine its enzyme activity with VD3, and only a low activity of human CYP27A1 toward VD3 (with Vmax of 0.27 mol/min/mol P450) was observed in this reaction system [29]. Although the 25-hydroxylation activity of human CYP27A1 was notably lower than that of several other mammalian CYPs such as human CYP2R1 (kcat = 0.61 min−1 for 25-hydroxylation activity toward vitamin D3 with CYP27A1 compared to kcat = 0.27 min−1 with CYP2R1), human CYP27A1 could perform 1α-hydroxylation toward calcifediol. Besides calcifediol and calcitriol, other products of human CYP27A1 hydroxylation include 26(OH)VD3, 24R,25(OH)2VD3, 27(OH)VD3, 25,26(OH)2VD3, 25,27(OH)2VD3, 27-oxo-VD3 and a dehydrogenated form of VD3, making the recovery of calcifediol or calcitriol much more difficult. In addition, ergosterol in the yeast membrane might inhibit the VD3 bioconversion as a potential substrate for CYP27A1. Therefore, compared with yeast, E. coli may be a better host for heterologous expression of mammalian CYPs due to its lack of the P450 genes and steroids [30].

Mitochondrial CYP27A1 in human liver is considered to be one of the CYPs that performs C-25 hydroxylation, while CYP27B1, another member of the CYP27 family, is responsible for hydroxylation at the C-1α position. However, Uchida et al. found that, by adding purified ADR and ADX to the reaction system, mouse CYP27B1 could perform both 25-hydroxylation and 1α-hydroxylation, similar to CYP27A1, suggesting that 1α-hydroxylation and 25-hydroxylation of vitamin D3 are closely related [23]. This observation led to the hypothesis that vitamin D3 can be arranged in the opposite direction of the substrate-binding pocket of CYP27B1. In addition, molecular chaperone GroEL/ES greatly enhanced the expression of mouse CYP27B1 in E. coli, making great progress for heterologous expression of CYPs in the future. In addition to mouse CYP27B1, human CYP27B1 also has 1α-hydroxylation activity [25]. However, the variant human CYP27B1 with CYP27B1T409I or CYP27B1Q65H amino acid substitution caused vitamin D 1α-hydroxylase deficiency (Vitamin D-dependent Rickets Type 1). The identification of amino acids that interact with the substrate could provide structural clues for the protein engineering of CYPs. The Ser408 residue in mouse CYP27B1 and the Thr409 residue in human CYP27B1 were found to be responsible for the C-1α hydroxylation by forming a hydrogen bond with the 25-hydroxyl group of calcifediol [31]. However, the problem with the low expression of human CYP27B1 still exists. Different strategies were thus employed to optimize the expression of human CYP27B1. High expression of human CYP27B1, shown by conversion to calcitriol with a yield of above 6000 pmol/mg protein in 30 min, was finally achieved by coexpressing GroEL/ES and human ADX/ADR rather than bovine ADX/ADR [32]. The addition of cardiolipin to the reconstituted system markedly lowered (threefold) the Km of human CYP27B1 for calcifediol, suggesting that the activity of CYPs could also be influenced by phospholipid composition.

Several other mammalian CYPs were also found to be relevant to VD3 hydroxylation. Both human CYP2R1 and human CYP27A1 can catalyze the 25-hydroxylation of VD3. However, the 25-hydroxylation activity of CYP2R1 on VD3 is five times higher than that of CYP27A1. In addition, a mutation in the human CYP2R1 gene results in vitamin D-dependent rickets [33]. These data indicate that CYP2R1 also plays an important role in calcifediol biosynthesis in human body [28]. The GroEL/ES chaperonin can also be used to increase the expression level of human CYP2R1 in E. coli [34]. To understand which amino acid residues are responsible for the substrate specificity of CYP2R1, the crystal structure of CYP2R1 in complex with VD3 was solved. VD3 binds in an elongated conformation with the aliphatic side-chain pointing to the heme. The substrate access channel is covered by the ordered B′-helix. The conserved active site in a closed conformation of CYP2R1 is mainly composed of hydrophobic amino acid residues. Porcine CYP2D25 was expressed in yeast by Hosseinpour [26] and Araya [35], and the substitution of five residues in substrate binding site 3 (SRS-3) inhibited its 25-hydroxylase activity. Besides 25-hydroxylase towards VD3, CYP2D25 is also able to convert calcifediol into calcitriol, 25,26(OH)2VD3, and 25,27(OH)2VD3.

Just like CYP2R1 as VD3 25-hydroxylase, the recombinant rat CYP2J3 shows a 25-hydroxylation activity when it was coexpressed with GroEL/ES in E. coli [27]. The turnover numbers were 3.3 and 22 toward VD3 and 1α(OH)VD3, respectively. Human CYP2J2 shows 73% amino acid homology with CYP2J3. After the deletion of a putative membrane anchor region in the N-terminus and the coexpression of GroEL/ES, efficient expression of CYP2J2 was achieved. However, human CYP2J2 does not seem to be a principal VD3 25-hydroxylase [36]. The CYP2C11, a male-specific hepatic recombinant microsomal vitamin D 25-hydroxylase, has a substrate preference toward VD3 over 1α(OH)VD3 [37]. The 25-hydroxylation activity of the CYP2C11 towards VD2 was higher than that towards VD3 (25-hydroxylation rate of 0.49 ± 0.03 nmol·nmol−1·1.5 h−1 for VD2 compared with 0.07 ± 0.02 nmol·nmol−1·1.5 h−1 for VD3). The examples of CYP2J2 and CYP2C11 imply that some CYPs from mammals take VD2 as a prioritized substrate and thus might not be the best choice for the hydroxylation of VD3.

CYPs from microorganisms

CYPs existing in a variety of organisms are involved in many biosynthetic pathways [20, 25]. Since the initial discovery of the VD3 hydroxylation in Amycolata sp. and Streptomyces sp. strains, CYPs from actinomycetes have been widely used for the VD3 bioconversion process [21, 22, 38, 39]. The 25-hydroxylation activity of VD3 by CYP105A2 (with the highest yield of 10%) was observed by heterologous expression of CYP105A2 from Amycolata autotrophica (Pseudonocardia autotrophica) in Streptomyces lividans [40]. Cytochrome P450SU-1 (CYP105A1) from Streptomyces griseolus was found to convert VD3 to 25(OH)VD3 when expressed in E. coli [41]. Although the amino acid sequences of CYP105A1 and CYP105A2 share 55% identity, there is a clear difference in catalytic activity between CYP105A1 and CYP105A2. Besides the 25-hydroxylation of VD3, CYP105A1 also shows 1α-hydroxylation of calcifediol. In addition, CYP105A1 can also catalyze the hydroxylation of VD2 with a relatively high Vmax/Km value (0.142 L−1·min−1/mol P450, compared to 30 L−1·min−1/mol P450 for VD3). The CYP107CB2 from Bacillus lehensis G1 was classified into the CYP107 subfamily and showed 25-hydroxylation activity of both VD3 and 1α(OH)VD3 [42].

CYPs that catalyze the hydroxylation of VD3 share a common catalytic mechanism with most CYPs. The catalytic cycle occurs on the heme prosthetic group which is linked by a conserved cysteine [43], but the catalytic specificity of CYPs mainly depends on their substrate binding pockets [44] (Fig. 2). Based on the catalytic mechanism, the catalytic specificity of CYP for VD3 can be improved by directed evolution of CYPs.

Fig. 2

Schematic representation of the substrate binding pocket. The substrate calcifediol is located in the substrate binding pocket in a suitable position, and will be further catalyzed by the Cys-linked heme

Structural analysis of CYP105A1 in complex with calcitriol found that Arg73 and Arg84 along with Arg193 were located in the distal pocket of CYP105A1. The Arg73 and Arg84 may have an inhibitory effect on activity, while Arg193 is required for the activity [39, 45, 46]. Therefore, a series of CYP105A1 variants focusing on residues Arg73 and Arg84 were made to achieve a higher activity (with relative kcat/Km compared with wild type ranging from 1 min−1·μM−1 to 43 min−1·μM−1 with 1α(OH)VD3 and calcifediol as substrate). Compared with the wild-type CYP105A1, the activity of CYP105A1R84A variant greatly increased, with activity of 25-hydroxylation toward 1α(OH)VD3 and 25-hydroxylation toward calcifediol are approximate 27-fold and 16-fold than CYP105A1WT, respectively. The improved activity can be attributed to the loss of two hydrogen bonds, which resulted in a new transient binding site for both the substrate and product [45]. The variant of CYP105A1 containing amino acid substitutions R73V and R84A exhibited much higher hydroxylation activities at positions C-1α and C-25 compared to the wild type; the CYP105A1R84A variant also shows a kcat/Km value for 25-hydroxylation that is 435-fold higher than that of the wild type; the CYP105A1R84A mutant also shows a higher 1α-hydroxylation capability than any single mutant. The amino acid residue at position 73 affects the location and conformation of the substrate in the reaction center, while the amino acid residue at position 84 affects the location and conformation of the transient binding site. In addition, the CYP105A1R73VR84A [39] also catalyzes the hydroxylation at position C-26, with 1α,25(R),26(OH)3VD3 and 1α,25(S),26(OH)3VD3 as products. The presence of C-26 hydroxylation activity could be caused by the rotation of a secosteroid skeleton and an evident conformational change of the side chain in the heme pocket.

Inspired by the engineering of CYP105A1R73VR84A, arginine residues around the substrate entrance and active site of CYP105D7 were mutated to generate a double mutant CYP105D7R70AR190A [47]. The CYP105D7R70AR190A achieved an almost ninefold increase in the conversion rate of testosterone, suggesting that the arginine residues around the substrate entrance and active site play important roles in determining the functions of the CYPs. Interestingly, the CYP105A1 is not the only VD3 hydroxylase found in P. autotrophica. Vdh (CYP107BR1) from P. autotrophica NBRC 12743 also has the capability of converting VD3 into calcifediol and calcitriol [48]. Different from other VD3 hydroxylases, the Vdh has no preferred regio-specific hydroxylation of VD3.

A Vdh variant designated as Vdh-K1 with four amino acid substitutions was obtained by means of random mutagenesis, with its activity an order of magnitude higher than that of wild-type Vdh. Yasutake et al. then analyzed the structures of Vdh and Vdh-K1 [49]. The wild-type Vdh showed an open conformation, and the distal heme pocket was exposed to solvent with or without substrate. In contrast, Vdh-K1 shows a closed conformation, increasing the substrate binding affinity and catalytic activity. In addition, the combination of VD3 and calcifediol with Vdh-K1 is in an antiparallel orientation. It is worth noting that the four substituted residues of Vdh-K1 are dispersed throughout the protein but result in a closed conformation of the heme pocket. The VdhT107A variant, which was made by modifying the putative ferredoxin-binding site of Vdh, also exhibited a closed conformation similar to Vdh-K1 bound to VD3 [50]. The ferredoxin-binding surfaces of VdhT107A seem to show a stronger positive potential that is conducive to the binding of ferredoxin when compared with the structures of Vdh-K1. Although the enzyme activity of Vdh-K1 was much higher than that of wild-type Vdh, its expression level in Rhodococcus erythropolis cells was low, in contrast with that of VdhT107A, which was approximately 70% of VdhWT. In addition, VdhT107A has an improved activity that is comparable to that of Vdh-K1, and achieves a similar expression that is comparable to Vdh simultaneously.

The above examples are the modification of the substrate binding pocket. Nevertheless, the engineering technology of CYPs has been greatly developed. Drawing on these technologies, it may be possible to use allosteric regulation, decoy-based small molecules etc., for reference in the hydroxylation of VD3 in the future. For example, the conformational transition of CYP3A4 is induced by the allosteric ligand progesterone (PGS), and CYP3A4-PGS conjugates thus acquire a twofold higher capacity to oxidize testosterone than CYP3A4 [51]. Inert decoy molecules that have a native substrate-like structure, can constrain substrates, such as benzene and benzene derivatives, into the suitable positions to facilitate the catalysis by targeting the enzyme substrate pocket to induce an active enzyme intermediate [52, 53]. If the above technologies are combined into the catalytic reaction of VD3, it may be possible to expand the types of CYPs that can be used to catalyze VD3, inspiring future research that may have unforeseen benefits.

Conversion of VD3 by steroid C25 dehydrogenase

Rugor et al. reported that steroid C25 dehydrogenase (S25DH) from the β-proteobacteria Sterolibacterium denitrificans was able to catalyze the regioselective hydroxylation of sterols and their derivatives [17]. The reaction was carried out in a batch reactor supplemented with purified S25DH (as the enzyme), VD3 (substrate), hydroxypropyl-β-cyclodextrin (solubilizer), 2-methoxyethanol (organic cosolvent) and K3[Fe(CN)6] (electron acceptor). A calcifediol titer of 1.4 g/L was achieved after a 162-h incubation, with a yield as high as 99%.

Compared with CYPs, S25DH has advantages as well as disadvantages. The catalytic activity of S25DH is higher than that of the CYPs reported thus far. In addition, the regioselectivity toward the C-25 position of VD3 is higher in S25DH than that in CYPs, making the recovery of calcifediol much easier. However, S25DH is sensitive to oxygen, so the bioconversion process must be carried out under anaerobic conditions [54]. Jacoby et al. developed a platform for the overproduction of four steroid C-25 hydroxylases (S25DH1 and three isoenzymes S25DH2, S25DH3, and S25DH4) by coexpressing an essential chaperone in the betaproteobacterium Thauera aromatica K172 [55]. The crude extract from T. aromatica that overexpresseed S25DH1 achieved a reaction rate that was 6.5-fold higher than that of the wild-type bacterial extract. However, the oxygen intolerance and high cost prevent S25DH from being applied for the industrial production of calcifediol.

Whole cell conversion of VD3 into calcifediol and calcitriol

A whole-cell conversion system expressing the CYPs of interest has advantages over enzymatic conversion. It avoids adding the expensive cofactor NAD(P)H, and the hydrogen dioxide produced by the uncoupling reactions does not accumulat because of the presence of catalase in the cell. Therefore, increasing attention has been given to the whole cell conversion of VD3 into calcifediol and calcitriol. initially, attempts were made to screen natural microbial strains that are able to convert VD3 to calcifediol and calcitriol in nature. With the development of genome editing and synthetic biology, the production of calcifediol and calcitriol has been further improved by either overexpressing heterogenous VD3 hydroxylase genes or altering the electron transfer chains.

Conversion of VD3 to calcifediol and calcitriol by microbes isolated in nature

Sasaki et al. reported the bioconversion of VD3 derivatives for the first time [21]. After screening approximately 300 Streptomyces strains, S. sclerotialus FERM BP-1370 and S. roseosporus FERM BP-1574 were found to be able to introduce hydroxy group at C-1α position of calcifediol and C-25 position of 1α(OH)VD3, respectively. Although VD3 derivatives were used as substrates rather than VD3 itself, this work demonstrated that microorganisms could be used for the production of hydroxylated derivatives of VD3. By further screening within bacterial and fungal strains, P. autotrophica FERM BP-1573 was chosen from twelve VD3-hydroxylating strains and achieved a calcifediol titer of 8.3 mg/L and a calcitriol titer of 0.17 mg/L in a 200 L fermenter [22].

With the ever-increasing number of newly discovered VD3-hydroxylating strains, the production of calcifediol and calcitriol has been further improved. The actinomycete Kutzneria albida produced 70.4 mg/L calcifediol and 2.0 mg/L calcitriol in an optimized conversion process [56]. When using Pseudonocardia sp. KCTC 1029BP as a whole-cell catalyst, calcifediol production further rose to 356 mg/L, and calcitriol production rose to 61.87 mg/L, with bioconversion yields of 59.4% and 30.94%, respectively [57, 58]. More recently, Tang et al. obtained up to 830 mg/L calcifediol using Bacillus cereus zju 4-2, representing a significant increase in calcifediol production [59] (Table 2). In addition to calcifediol and calcitriol, some side products of VD3 hydroxylation such as 2α,25(OH)2VD3 could also be synthesized, increasing the difficulty of product recovery [60]. It is of great significance to reduce the formation of side products by isolating a microbial strain with high regioselectivity.

Table 2

Whole-cell bioconversion of VD3 to calcifediol and calcitriol

Strains	Titer (mg/L)	Productivity(mg/L/d)	Yield(g/g)	References
Calcifediol
Pseudonocardia autotrophica FERM BP-1573	8.3	2.6	NA	[21, 22]
Pseudonocardia sp. KCTC 1029BP	356	71.2	0.59	[58]
Pseudonocardia autotrophica CGMCC5098	639	127.8	0.61	[75]
Bacillus cereus zju 4–2	830	415.0	0.42	[59]
Kutzneria albida	70	35.2	0.14	[56]
Calcitriol
Pseudonocardia autotrophica FERM BP-1573	0.17	/	NA	[22]
Pseudonocardia sp. KCTC 1029BP	62	6.9	0.31	[58]
Pseudonocardia autotrophica 100U-19	32	10.7	NA	[60]
Kutzneria albida	2	1.0	NA	[56]

Though many attempts have been made to enhance the calcifediol and calcitriol production, the acquirable concentrations of calcifediol and calcitriol in the fermentation broth are not yet satisfactory. Therefore, a series of fermentation parameters have been optimized to further improve the production of calcifediol and calcitriol. The influence of bioconversion buffers, solubilizers, and metal salts on calcitriol production has also been examined, and optimized bioconversion medium was finally been obtained. The optimization of three key variables (aeration rate, resting cell concentration and temperature) in Pseudonocardia fermentation improves the VD3 bioconversion [57, 58].

Conversion of VD3 to calcifediol and calcitriol by engineered strains

With the development of genomics and synthetic biology, engineering of microbial cells provides a new strategy to improve the production of calcifediol and calcitriol. Besides previously mentioned heterologous expression of CYPs for purpose of enzymatic activity characterization and structural analysis, design of engineered strains for whole-cell bioconversion could be applied for industrial-scale production of calcifediol and calcitriol. Actinomycete chassis cells such as S. lividans and R. erythropolis have stable redox environments, which may explain why most bacterial VD3-hydroxylating CYPs have been discovered in actinomycetes; thus, these cells could be promising chassis cells for calcifediol and calcitriol production. When expressing CYP105A1R73VR84A in S. lividans, approximately 7.7 mg/L calcifediol was observed in the culture [39]. R. erythropolis is another industrially important actinomycete that exhibits resistance to organic solvents, so it was used as a host cell to convert VD3 to calcifediol and calcitriol [61] (Fig. 3). The permeability of VD3 into the cytoplasm is a rate-limiting step for VD3 bioconversion [62]. In addition, the electron carrier ferredoxin and the NADH-regeneration system also play essential roles in the conversion of VD3 to its bioactive form. When Vdh was coexpressed with the redox partners AciBC and glucose dehydrogenase GlcDH-IV in nisin-treated R. erythropolis cells, 1176.5 μg calcifediol was obtained, representing an improved calcifediol production when compared with the wild-type strain [61]. Deletion of CYP-sb3 gene dramatically impaired the VD3 bioconversion of by Sebekia benihana, suggesting that CYP-sb3a functions as a VD3 hydroxylase. When CYP-sb3a was expressed in Streptomyces coelicolor that originally had no VD3 hydroxylation ability, calcifediol and calcitriol were detected in the recombinant S. coelicolor cells [63]. B. megaterium is another popular host that has been used for VD3 bioconversion (Fig. 4). When B. megaterium expressing human CYP27A1 was used as whole-cell catalyst, 80.81 mg/L VD3 was converted to its bioactive form. In addition, B. megaterium overexpressing CYP109A2T103A produced 282.7 mg/L calcifediol in 48 h under optimized conditions. Though there are still technical challenges for calcifediol and calcitriol production by engineered strain, designing better artificial strains is a promising strategy to further enhance the calcifediol and calcitriol production by designing better artificial strains.

Fig. 3

NAD(P)H-regeneration system enhances the bioconversion of VD3 to calcifediol and calcitriol in engineered R. erythropolis. Sufficient reducing equivalents (NADH/NADPH) obtained by the NAD(P)H-regeneration system (GlcDH from B. megaterium) provide more electrons required for the catalysis of the hydroxylation reaction. Moreover, nisin treatment contributes to increased permeability of the cell membrane

Fig. 4

B. megaterium is used as a host cell for VD3 bioconversion. The electrons required for CYP activity are supplied by the endogenous cytochrome P450 reductase (CPR): NADPH-dependent diflavin reductase [76]. Quillaja saponin is used as a membrane-solubilizing agent

With the help of the NADPH-regenerating system, approximately 40% VD3 was converted to calcifediol in 3 hours. The CYP109A2 [64] and CYP109E1 [65] from Bacillus megaterium also exhibited high VD3 bioconversion abilities. After 24 h of whole-cell catalysis, the conversion rates of CYP109A2 and CYP109E1 reached 76% and 95%, respectively. However, NMR analysis showed that CYP109E1 catalyzed the hydroxylation of VD3 at both C-24 and C-25. Approximately twofold more calcifediol was produced in the CYP109E1I85A variant obtained by site-directed mutation than in the wild-type CYP109E1 through whole-cell bioconversion, suggesting that the CYP109E1I85A variant achieves improved selectivity for 25-hydroxylation of VD3. In addition, after a 48-h incubation under optimized conditions, 282.7 mg/L calcifediol was produced by CYP109A2T103A, a more efficient variant obtained by protein engineering of CYP109A2 [66].

The highest yield by engineered strains was achieved by the protein engineering of Vdh (CYP107BR1). For the Vdh and its variants, when R. erythropolis cells expressing VdhT107A were treated with nisin for VD3 conversion, 573 mg/L calcifediol was produced in 2 hours, representing a significantly improved bioconversion rate. Compared with wild-type Vdh, a 1.7-fold of calcifediol production was observed in shorter time (2 h compared with 16 h).

Whether by isolated strains or engineered strains, the efficiency of the VD3 bioconversion process is limited in different levels, mainly genes expression, enzyme activity, efficiency of CYP-redox partner interactions, the NAD(P)H regeneration system and the substrate transportation. Since various efforts have been made in optimizations, a combination of different methods could result in a higher yield. For example, with E. coli as the host, not only by expression of high enzymatic activity CYPs which are assisted with adequate Fdr and Fdx, the introduction of GroEL/ES system along with the mutation of genes include acrAB and tolC [67], whose expression products compose a efflux pump system which play positive roles simultaneously. The deletion of acrAB and tolC in E. coli BL21star(DE3) works similar to the nisin treatment for R. erythropolis, which can increase in the intracellular substrate concentration. In addition, in the fermentation process, the addition of Fe2+ and 5-aminolevulinic acid (5-ALA) [68], which is precursor of heme can be adopted in most cases to ensure the functional expression of CYPs.

In addition to improving the transportation of substrates, there are other potential methods of improving VD3 bioconversion. CYPs displayed on the cell surface of E. coli [69, 70] will provide alternative solution for the transportation of VD3. In the meanwhile, this method could be also used for the screening of highly efficient VD3 hydroxylases. The fusion of CYPs and redox partners could construct a self-sufficient P450 [71], which is promising for future methods of VD3 bioconversion.

Conclusions

Calcifediol and calcitriol have bright market prospects in the poultry farming and pharmaceutical industries. Compared with the traditional chemical synthesis, bioconversion of VD3 to calcifediol and calcitriol represents a promising and eco-friendly technology, and will contribute to the sustainable development goals of United Nations. Given that VD3 hydroxylase plays a key role in the bioconversion of VD3 to calcifediol and calcitriol, a series of CYPs have been modified by protein engineering to increase their catalysis of VD3 hydroxylation. In addition, the VD3 permeability and the electron transfer from NADH to VD3 hydroxylase are also of great importance in determining the rate of VD3 bioconversion. Therefore, the lipid II-targeting antibiotic nisin, redox partners and NAD(P)H regeneration systems are employed to further improve the VD3 bioconversion by enhancing the VD3 uptake and optimizing the electron transfer pathway. High-throughput screening technology has shown its advantages in the field of strain screening [72], and high-throughput screening based on the calcifediol/calcitriol sensor can be used to screen microbial strains that are capable of converting VD3 to calcifediol or calcitriol more efficiently.

With increasing pressure to conserve energy and protect the environment, increasing attention is being paid to the bioproduction of value-added chemicals in a more eco-friendly manner [73, 74]. The “next generation industrial biotechnology” based on moderately halophilic bacteria, which can avoid sterilization and the use of fresh water, exhibits advantages over the current industrial biotechnology. Given that a large number of VD3-hydroxylating strains belong to actinomycetes, efficient screening of halophilic actinomycetes could be a promising strategy to obtain more ideal calcifediol/calcitriol-producing strains. In addition, engineering of the well-studied halophilic bacteria such as Halomonas bluephagenesis could be another promising strategy to further improve the calcifediol/calcitriol production in the future.